|
Age at BM diagnosis (years)- median (range)
| | | | | |
|
< 65 years
|
54(34-83)
|
53 (33- 75)
|
47(26-67)
|
52(26-83)
|
0.0178
|
|
≥ 65 years
|
59/77 (76.62)
|
15/20 (75)
|
31/32 (96.88)
|
105/129 (81.4)
| |
| |
18/77 (23.38)
|
5/20 (25)
|
1/32 (3.12)
|
24/129 (18.6)
| |
|
Karnofsky performance status
| | | | | |
|
< 70
|
32/76 (42.11)
|
10/20 (50)
|
6/31 (19.35)
|
48/127 (37.8)
|
0.0418
|
|
≥ 70
|
44/76 (57.89)
|
10/20 (50)
|
25/31 (80.65)
|
79/127 (62.2)
| |
|
RTOG RPA class
|
0
|
0
|
0
|
0
|
0.0391
|
|
I
|
43/75 (57.33)
|
10/20 (50)
|
25/31 (80.65)
|
78/126 (61.9)
| |
|
II
|
32/75 (42.67)
|
10/20 (50)
|
6/31 (19.35)
|
48/126 (38.1)
| |
|
III
| | | | | |
|
Histology of primary BC
| | | | | |
|
Ductal
|
70/76 (92.11)
|
19/20 (95)
|
30/32 (93.75)
|
119/128 (92.97)
|
0.5172** (ns)
|
|
Lobular
|
2/76 (2.63)
|
0
|
2/32 (6.25)
|
4/128 (3.12)
| |
|
Other
|
4/76 (5.26)
|
1/20 (5)
|
0
|
5/128 (3.91)
| |
|
Histologic grade
| | | | | |
|
SBR I
|
2/70 (2.86)
|
1/17 (5.88)
|
1/31 (3.23)
|
4/118 (3.39)
|
0.063** (ns)
|
|
SBR II
|
27/70 (38.57)
|
1/17 (5.88)
|
11/31 (35.48)
|
39/118 (33.05)
| |
|
SBRIII
|
41/70 (58.57)
|
15/17 (88.24)
|
19/31 (61.29)
|
75/118 (63.56)
| |
|
Tumor HR status
| | | | | |
|
Positive
|
48/76 (63.16)
|
9/19 (47.37)
|
17/32 (53.12)
|
72/127 (56.69)
|
0.1996 (ns)
|
|
Negative
|
28/76 (36.84)
|
10/19 (52.63)
|
15/32 (46.88)
|
55/127 (43.31)
| |
|
Number of BM
| | | | | |
|
Single
|
6/78 (7.69)
|
0
|
0
|
6/130 (4.62)
|
0.1339** (ns)
|
|
Multiple
|
72/78 (92.31)
|
20/20 (100)
|
32/32 (100)
|
124/130 (95.38)
|
0.1778 **(ns)
|
|
Meningitis
|
17/77 (22.08)
|
1/20 (5)
|
4/31 (12.9)
|
22/128 (17.19)
| |
|
Yes
|
60/77 (77.92)
|
19/20 (95)
|
27/31 (87.1)
|
106/128 (82.81)
| |
|
No
| | | | | |
|
Number of other metastatic sites
| | | | | |
|
0 (BM alone)
|
6/78 (7.69)
|
1/20 (5)
|
0
|
7/130 (5.38)
|
0.2971** (ns)
|
|
1
|
19/78 (24.36)
|
3/20 (15)
|
9/32 (28.12)
|
31/130 (23.85)
| |
|
2
|
20/78 (25.64)
|
7/20 (35)
|
14/32 (43.75)
|
41/130 (31.54)
| |
|
> 2
|
33/78 (42.31)
|
9/20 (45)
|
9/32 (28.12)
|
51/130 (39.23)
| |
|
Concomitant and other metastases
| | | | | |
|
Liver
|
35/78 (44.87)
|
12/20 (60)
|
23/32 (71.88)
|
70/130 (53.85)
|
0.0299
|
|
Lung
|
36/78 (46.15)
|
11/20 (55)
|
14/32 (43.75)
|
61/130 (46.92)
|
0.7147 (ns)
|
|
Bone
|
51/78 (65.38)
|
10/20 (50)
|
18/32 (56.25)
|
79/130 (60.77)
|
0.3783 (ns)
|
|
Previous chemotherapy
|
55/78 (70.51)
|
18/20 (90)
|
32/32 (100)
|
105/130 (80.77)
|
0.0002**
|
|
Yes
|
23/78 (29.49)
|
2/20 (10)
|
0
|
25/130 (19.23)
| |
|
No
| | | | | |
|
Previous taxane-based chemotherapy
|
36/78 (46.15)
|
11/20 (55)
|
25/31 (80.65)
|
72/129 (55.81)
|
0.0047
|
|
Yes
|
42/78 (53.85)
|
9/20 (45)
|
6/31 (19.35)
|
57/129 (44.19)
| |
|
No
| | | | | |
|
Lactate Deshydrogenase (LDH)
|
35/61 (57.38)
|
9/14 (64.29)
|
13/19 (68.42)
|
57/94 (60.64)
|
0.6597 (ns)
|
|
≤ 500 UI/L
|
26/61 (42.62)
|
5/14 (35.71)
|
6/19 (31.58)
|
37/94 (39.36)
| |
|
500 UI/L
|
127-2088
|
120-3469
|
158-2199
|
120-3469
| |
|
range
| | | | | |
|
Lymphocyte count
|
25/70 (35.71)
|
9/20 (45)
|
3/20 (15)
|
37/110 (33.64)
|
0.1106 (ns)
|
|
≤ 0.7 G/L
|
45/70 (64.29)
|
11/20 (55)
|
17/20 (85)
|
73/110 (66.36)
| |
|
> 0.7 G/L
|
61-2285
|
40-1814
|
63-2050
|
40-2285
| |
|
range
| | | | | |
|
Vital Status
|
16/78 (20.51)
|
2/20 (10)
|
14/32 (43.75) 18/32 (56.25)
|
32/130 (24.62)
|
0.0138**
|
|
alive
|
62/78 (79.49)
|
18/20 (90)
| |
98/130 (75.38)
| |
|
dead
| | | | | |
